508PD2ND-LINE THERAPIES AFTER 1ST-LINE THERAPY WITH FOLFIRI IN COMBINATION WITH CETUXIMAB OR BEVACIZUMAB IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)-ANALYSIS OF THE AIO KRK 0306 (FIRE 3)- TRIAL.
Annals of oncology : official journal of the European Society for Medical Oncology(2014)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要